SCHEMBL9922968

SCHEMBL9922968

CNc1ccc2c(=O)n(-c3c(F)cc(NC(=O)NS(=O)(=O)c4cc(Cl)c(C)s4)cc3C(F)(F)F)c(=O)[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.51
AR P10275 1/20 0.36
TRPV1 Q8NER1 2/20 0.34
CA9 Q16790 4/20 0.33
ERCC1 P07992 1/20 0.32
FEN1 P39748 1/20 0.32
ERCC4 Q92889 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
RAF1 P04049 1/20 0.31
MAPK3 P27361 1/20 0.31
KDR P35968 1/20 0.31
BRAF P15056 3/20 0.31
CA1 P00915 3/20 0.31
CA2 P00918 2/20 0.31
CA7 P43166 2/20 0.31
FBP1 P09467 1/20 0.30
MAPT P10636 1/20 0.30
CA12 O43570 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12161650 0.94 P2RY12 (0.52) P2RY12ARTRPV1CA9ERCC1
SCHEMBL9922966 0.93 P2RY12 (0.55) P2RY12ARCA9ERCC1FEN1
SCHEMBL14228360 0.92 P2RY12 (0.52) P2RY12ARTRPV1CA9ERCC1
SCHEMBL9922967 0.92 P2RY12 (0.54) P2RY12CA9ERCC1FEN1ERCC4
SCHEMBL9923174 0.91 P2RY12 (0.62) P2RY12ARTRPV1ERCC1FEN1
SCHEMBL12177394 0.90 P2RY12 (0.52) P2RY12ARTRPV1CA9ERCC1
SCHEMBL12177673 0.90 P2RY12 (0.52) P2RY12CA9ERCC1FEN1ERCC4
SCHEMBL9922963 0.89 P2RY12 (0.51) P2RY12ARTRPV1CA9ERCC1
SCHEMBL12161651 0.87 P2RY12 (0.57) P2RY12CA9ERCC1FEN1ERCC4
SCHEMBL9922980 0.87 P2RY12 (0.47) P2RY12ARTRPV1ERCC1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885AR 1502/4885TRPV1 577/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885AR 1461/4885TRPV1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.